Miao-Zhen Qiu
Overview
Explore the profile of Miao-Zhen Qiu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
131
Citations
3088
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Qiu M, Bai Y, Wang J, Gu K, Yang M, He Y, et al.
Signal Transduct Target Ther
. 2024 Dec;
9(1):349.
PMID: 39676137
This phase 2/3 trial (NCT04856787) assessed the efficacy and safety of SHR-1701, a bifunctional protein targeting PD-L1 and TGF-β, in combination with BP102 (a bevacizumab biosimilar) and XELOX (capecitabine plus...
2.
Luo Q, Yang J, Di T, Xia Z, Zhang L, Pan W, et al.
Acta Pharmacol Sin
. 2024 Nov;
PMID: 39592733
HER2-positive gastric cancer has a poor prognosis, with a high incidence of drug resistance and a lack of effective treatments for drug-resistant patients. The exploration of the mechanism of resistance...
3.
Di T, Luo Q, Song J, Yan X, Zhang L, Pan W, et al.
Int Immunopharmacol
. 2024 Jul;
139:112615.
PMID: 39032475
Background And Purpose: Liver cancer is the fourth leading cause of cancer-related death worldwide, with hepatocellular carcinoma (HCC) being the most common type of primary liver cancer. APG-1252 is a...
4.
Sun Y, Lu S, Lai M, Yang X, Guan W, Yang L, et al.
Cancer Immunol Immunother
. 2024 Jun;
73(8):144.
PMID: 38832979
Background: The beneficial effects of first-line programmed death-1 (PD-1) inhibitors plus chemotherapy in patients with low programmed death-ligand 1 (PD-L1)-expressing advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma are controversial. Methods:...
5.
Qiu M, Oh D, Kato K, Arkenau T, Tabernero J, Correa M, et al.
BMJ
. 2024 May;
385:e078876.
PMID: 38806195
Objective: To evaluate the efficacy and safety of tislelizumab added to chemotherapy as first line (primary) treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma compared with placebo plus chemotherapy. Design:...
6.
Pan W, Luo Q, Liang E, Shi M, Sun J, Shen H, et al.
Cancer Cell Int
. 2024 May;
24(1):181.
PMID: 38790057
Background: Immune checkpoint inhibitors are approved for the treatment of various tumors, but the response rate is not satisfactory in certain malignancies. Inhibitor of apoptosis proteins (IAP) ubiquitin-E3 ligase activity...
7.
Li J, Lai M, Lin Z, Guan W, Sun Y, Yang J, et al.
Cancer Immunol Immunother
. 2024 May;
73(7):132.
PMID: 38753055
Background: Immune checkpoint inhibitors (ICIs) combined with chemotherapy have become the first-line treatment of metastatic gastric and gastroesophageal adenocarcinomas (GEACs). This study aims to figure out the optimal combined positive...
8.
Wang D, Ren C, Li S, Pat Fong W, Wu X, Xiao J, et al.
PLoS Med
. 2024 May;
21(5):e1004389.
PMID: 38728364
Background: It remains unclear whether intensification of the chemotherapy backbone in tandem with an anti-EGFR can confer superior clinical outcomes in a cohort of RAS/BRAF wild-type colorectal cancer (CRC) patients...
9.
Wang F, Jin Y, Wang M, Luo H, Fang W, Wang Y, et al.
Nat Med
. 2024 Mar;
30(4):1035-1043.
PMID: 38438735
Epigenetic modifications of chromatin, including histone acetylation, and tumor angiogenesis play pivotal roles in creating an immunosuppressive tumor microenvironment. In the randomized phase 2 CAPability-01 trial, we investigated the potential...
10.
Wang F, Zhang X, Tang L, Wu Q, Cai M, Li Y, et al.
Cancer Commun (Lond)
. 2023 Dec;
44(1):127-172.
PMID: 38160327
The 2023 update of the Chinese Society of Clinical Oncology (CSCO) Clinical Guidelines for Gastric Cancer focuses on standardizing cancer diagnosis and treatment in China, reflecting the latest advancements in...